Vanta Bioscience Limited (BOM:540729)
India · Delayed Price · Currency is INR 22.83
0.00 (0.00%)
At close: Aug 5, 2026
Vanta Bioscience Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 1.35 | 2.22 | 1.61 | 0.97 | 2.24 |
Cash & Short-Term Investments | 1.35 | 2.22 | 1.61 | 0.97 | 2.24 |
Cash Growth | -38.89% | 37.93% | 66.20% | -56.90% | -91.54% |
Accounts Receivable | 25.58 | 25.03 | 31.41 | 19.59 | 11.34 |
Other Receivables | - | 40.63 | 41.29 | - | 37.21 |
Receivables | 59.36 | 65.66 | 72.7 | 73.39 | 48.55 |
Inventory | 75.28 | 65.07 | 75.21 | 71.58 | 72.36 |
Prepaid Expenses | - | 0.5 | 0.46 | - | 1.27 |
Other Current Assets | 5.33 | 20.12 | 21.64 | 6.5 | 20.57 |
Total Current Assets | 141.32 | 153.57 | 171.61 | 152.43 | 144.98 |
Property, Plant & Equipment | 96.77 | 239.62 | 284.06 | 332.29 | 373.15 |
Long-Term Investments | 30 | 9.1 | 9.1 | 9.1 | 14.2 |
Other Intangible Assets | 384 | 315.37 | 257.47 | 106.04 | 56.88 |
Long-Term Deferred Charges | - | 134.66 | 125.34 | 239.95 | 215.86 |
Other Long-Term Assets | 8.93 | 6.47 | 6.39 | 7.28 | 8.96 |
Total Assets | 661.03 | 858.79 | 853.97 | 847.09 | 814.04 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 16.09 | 49.45 | 55.69 | 42.19 | 24.64 |
Accrued Expenses | - | 45.6 | 39.74 | 26.5 | 32.89 |
Short-Term Debt | - | 48.21 | 43.39 | 2.91 | 32.21 |
Current Portion of Long-Term Debt | 68.71 | 111.38 | 77.22 | 98.04 | 46.49 |
Current Income Taxes Payable | - | - | - | - | 0.39 |
Other Current Liabilities | 33.42 | 11 | 11.82 | 7.83 | 6.17 |
Total Current Liabilities | 118.21 | 265.64 | 227.86 | 177.47 | 142.79 |
Long-Term Debt | 312.08 | 541.25 | 488.92 | 470.67 | 369.97 |
Long-Term Deferred Tax Liabilities | 6.48 | 14.06 | 7.45 | 9.65 | 7.84 |
Other Long-Term Liabilities | 12.5 | - | - | -0 | - |
Total Liabilities | 449.27 | 820.96 | 724.23 | 657.79 | 520.6 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 71.12 | 63.12 | 63.12 | 63.12 | 63.12 |
Additional Paid-In Capital | - | 152.12 | 152.12 | 152.12 | 152.12 |
Retained Earnings | - | -111 | -63.25 | -40.09 | 24.83 |
Comprehensive Income & Other | 140.64 | - | - | - | - |
Total Common Equity | 211.76 | 104.24 | 151.99 | 175.15 | 240.07 |
Minority Interest | - | -66.41 | -22.26 | 14.15 | 53.37 |
Shareholders' Equity | 211.76 | 37.83 | 129.73 | 189.3 | 293.44 |
Total Liabilities & Equity | 661.03 | 858.79 | 853.97 | 847.09 | 814.04 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 380.78 | 700.84 | 609.54 | 571.61 | 448.67 |
Net Cash (Debt) | -379.43 | -698.62 | -607.93 | -570.65 | -446.43 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -52.55 | -110.68 | -96.31 | -90.41 | -70.73 |
Filing Date Shares Outstanding | 7.33 | 6.31 | 6.31 | 6.31 | 6.06 |
Total Common Shares Outstanding | 7.33 | 6.31 | 6.31 | 6.31 | 6.06 |
Working Capital | 23.11 | -112.07 | -56.25 | -25.04 | 2.19 |
Book Value Per Share | 28.87 | 16.51 | 24.08 | 27.75 | 39.63 |
Tangible Book Value | -172.25 | -211.13 | -105.48 | 69.11 | 183.19 |
Tangible Book Value Per Share | -23.48 | -33.45 | -16.71 | 10.95 | 30.24 |
Land | - | 11.79 | 11.75 | - | - |
Buildings | - | 99.67 | 99.67 | - | - |
Machinery | - | 321.83 | 318.07 | - | - |